FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 158 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 New on NCI’s Websites for March 2019 March 29, 2019 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... April 6, 2022 Load more HOT NEWS Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... 7 ways we’ve influenced progress in lung cancer Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage...
